Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2026-05-24 Share Issue/Capital Cha…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - BOT 7 pages 20.3KB
Share Issue/Capital Change Classification · 85% confidence The document is an ASX Appendix 2A “Application for quotation of securities,” detailing the conversion of performance rights into ordinary shares and the application for additional securities to be quoted. This is a capital change/share issue announcement under ASX Listing Rule requirements. It is not a financial report, AGM materials, or any other regulatory filing category, but specifically a share issue/capital change notice.
2026-05-24 English
Notification of cessation of securities - BOT 7 pages 21.9KB
Share Issue/Capital Change Classification · 85% confidence The document is an ASX Appendix 3H form notifying the market of the cessation (lapse/cancellation) of various equity securities (options and performance rights) under the company’s employee incentive plan. This is not a financial report or earnings release but a formal notice of changes to the company’s capital structure (issued and unquoted equity securities). Under our taxonomy, announcements of changes to share capital (including new issues, lapses, splits, cancellations, etc.) fall under “Share Issue/Capital Change” (SHA).
2026-05-20 English
Application for quotation of securities - BOT 8 pages 21.3KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX Appendix 2A application for quotation of securities, detailing the issue of 3,750,000 new ordinary shares upon conversion of performance rights. This is a formal announcement of a new share issue/capital change under ASX Listing Rules. It aligns with the “Share Issue/Capital Change” category.
2026-05-12 English
Securities Trading Policy 11 pages 344.8KB
Regulatory Filings
2026-05-07 English
Botanix announces change of address 1
Regulatory Filings Classification · 95% confidence The document is a short announcement about a change of the company's registered office and principal place of business address. It does not contain any financial data, report content, or regulatory filings related to financial performance, management changes, or shareholder votes. It is simply a corporate announcement about an administrative change. This type of announcement does not fit into categories like Annual Report, Interim Report, Management Information, or Capital Updates. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories. The document length is short (1435 characters), and it is not a report publication announcement or certification.
2026-05-05 English
Botanix appoints Chief Operating Officer 2 pages 226.3KB
Board/Management Information Classification · 100% confidence The document is a company announcement dated 4 May 2026 about the appointment of a new Chief Operating Officer at Botanix Pharmaceuticals. It focuses on management changes, detailing the promotion of Paul Seaback to COO and his background. There is no financial data, no mention of financial results, reports, or regulatory filings. The content is clearly about a change in senior management personnel. Therefore, the document fits the category of Board/Management Information (MANG). The document length is about 5061 characters, which is consistent with a typical management announcement. No other categories such as financial reports, earnings, or regulatory filings apply here.
2026-05-03 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.